An analysis of pre-treatment tumor specimens from 105 patients with localized muscle-invasive bladder cancer found that the presence of a mutation in any one of three genes, all known to be involved in DNA damage repair, was associated with complete pathologic response to cisplatin-based neoadjuvant chemotherapy as measured by pathological downstaging at the time of bladder surgery.